NewAmsterdam Pharma Company N.V. (NAMSW) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Naarden, Netherlands. The current CEO is Michael Harvey Davidson Facp..
NAMSW has IPO date of 2021-02-10, 68 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $2.69B.
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.
